Zhitong Finance App News, ST Renfu (600079.SH) issued an announcement. Recently, the company's holding subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (“Yichang Renfu”, the company holds 80% of its shares) received a marketing license approval letter approved by the British Medicines and Health Products Regulatory Authority (MHRA) to approve and issue a marketing license approval letter for dextrose sodium injection.

Sulgen Glucose Sodium Injection has obtained marketing approval from the MHRA in the UK. The approved indications are: antagonizing rocuronium bromide or vecuronium bromide induced neuromuscular block in adults; for pediatric patients from birth to age 17, it is currently only recommended for routine antagonism to block induced by rocuronium bromide.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.